LP01™ + LPC09 (BIFIPROST)
Urology
Prostate health
Anti-inflammatory activity
Inhibits pathogenic E. coli
Helps prevent chronic bacterial prostatitis
Degrades oxalate, the primary material in kidney stones
Reduces intestinal inflammation
1) LP01 and LPC09 1 billion cells each + plant extracts + serenoa repens
Blend
Finished dosage form
1) Chiancone F. et al. The Use of a Combination of Vaccinium Macracarpon, Lycium barbarum L. and Probiotics (Bifiprost®) for the Prevention of Chronic Bacterial Prostatitis: A Double-Blind Randomized Study. Urologia Internationalis 2019;103(4):423-426 DOI: 10.1159/000502765
a) Deidda F, et al. How Probiotics may Kill Harmful Bacteria: The in vitro Activity against Some Haemolytic Strains. J Prob Health, 2020. Vol. 8 Iss.2 No: 216. DOI: 10.35248/2329-8901.20.8.216
b) Mogna L. et al. Assessment of the In Vitro Inhibitory Activity of Specific Probiotic Bacteria Against Different Escherichia coli strains. J. Clin. Gastroenterol. 2012;46 Suppl.S29-32. Doi: 10.1097/MCG.0b013e31826852b7
c) Amoruso A. et al. A Systematic Evaluation of the Immunomodulatory and Functional Properties of Probiotic Bifidobacterium Breve BR03 (DSM 16604) Lactobacillus plantarum LP01 (LMG P-21021). J Prob Health. 2019; 7:214. Doi: 10.35248/2329-8901.19.7.214
d) Mogna L. et al. Screening of different probiotic strains for their in vitro ability to metabolise oxalates: any prospective use in humans? (LPC09, LA02, LP01, LRE02, BR03, BL03) J Clin Gastroenterol. 2014; 48 Suppl:S91-95.
Internal data on anti-inflammatory and anti-oxidant properties available upon request.
